The steady increase in stocks shifting into long-term bear market trends has implications for the broader market as we head into 2025. The negative momentum that is building is likely to create a ...

ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S.

Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.

With its stock down 12% over the past three months, it is easy to disregard Johnson & Johnson (NYSE:JNJ). However, stock ...

Royal Bank of Canada recently reported solid results that showed year-over-year growth in most areas. Find out why RY stock ...

Currently, the analyst consensus on Johnson & Johnson is a Moderate Buy with an average price target of $176.92, representing a 20.98% upside. In a report released on December 11, Citi also maintained ...

In a report released on December 10, Alistair Campbell from RBC Capital maintained a Buy rating on Genmab A/S (0MGB – Research Report), with a ...

BofA Securities has recently resumed Johnson & Johnson (JNJ) stock to Neutral rating, as announced on December 10, 2024, according to Finviz. Earlier, on November 15, 2024, Wolfe Research had ...